Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

Introduction Durvalumab has been shown to confer a survival benefit after definitive chemoradiotherapy in the patients with locally advanced non-small cell lung cancer, but no studies have attempted to identify risk factors for pneumonitis after durvalumab therapy. The purpose of this study was to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Hiroto, Ono, Akira, Kawabata, Takanori, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Yasui, Kazuaki, Ogawa, Hirofumi, Onoe, Tsuyoshi, Endo, Masahiro, Harada, Hideyuki, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497668/
https://www.ncbi.nlm.nih.gov/pubmed/32128667
http://dx.doi.org/10.1007/s10637-020-00917-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497668/
https://www.ncbi.nlm.nih.gov/pubmed/32128667
http://dx.doi.org/10.1007/s10637-020-00917-2

Ejemplares similares